journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://www.readbyqxmd.com/read/28741619/pancreatic-cancer-egfr-inhibition-is-effective-against-kras-wild-type-disease
#1
Peter Sidaway
No abstract text is available yet for this article.
July 25, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28741618/the-immune-contexture-in-cancer-prognosis-and-treatment
#2
REVIEW
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer
Immunotherapy is currently the most rapidly advancing area of clinical oncology, and provides the unprecedented opportunity to effectively treat, and even cure, several previously untreatable malignancies. A growing awareness exists of the fact that the success of chemotherapy and radiotherapy, in which the patient's disease can be stabilized well beyond discontinuation of treatment (and occasionally is cured), also relies on the induction of a durable anticancer immune response. Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy-induced immune response...
July 25, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28741617/gastrointestinal-cancer-establishing-a-family-tree
#3
Diana Romero
No abstract text is available yet for this article.
July 25, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28719587/outcomes-research-integrating-pros-into-the-clinic-overall-survival-benefit-or-not-it-s-worth-the-trouble
#4
Elisa Sperti, Massimo Di Maio
No abstract text is available yet for this article.
July 18, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28719586/breast-cancer-profiling-of-ultra-low-risk-disease
#5
David Killock
No abstract text is available yet for this article.
July 18, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28719585/immunotherapy-reality-check-for-nivolumab-in-advanced-stage-melanoma
#6
Diana Romero
No abstract text is available yet for this article.
July 18, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28719584/health-policy-me-too-drugs-with-limited-benefits-the-tale-of-regorafenib-for-hcc
#7
Bishal Gyawali, Vinay Prasad
No abstract text is available yet for this article.
July 18, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28719583/prevention-low-fat-diet-linked-to-decline-in-breast-cancer-mortality
#8
Lisa Hutchinson
No abstract text is available yet for this article.
July 18, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28719582/prostate-cancer-mutations-in-ctdna-reflect-features-of-metastatic-disease
#9
Peter Sidaway
No abstract text is available yet for this article.
July 18, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28695914/genetics-brca-mutant-breast-ovarian-cancer-revealed
#10
Peter Sidaway
No abstract text is available yet for this article.
July 11, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28695913/melanoma-neadjuvant-braf-inhibition-enables-resection
#11
Peter Sidaway
No abstract text is available yet for this article.
July 11, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28695912/targeted-therapy-ctdna-identified-in-patients-with-cup
#12
Peter Sidaway
No abstract text is available yet for this article.
July 11, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28695911/haematological-cancer-low-dose-car-t-cells-are-safe-and-effective
#13
Peter Sidaway
No abstract text is available yet for this article.
July 11, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28675165/precision-medicine-based-on-epigenomics-the-paradigm-of-carcinoma-of-unknown-primary
#14
REVIEW
Sebastián Moran, Anna Martinez-Cardús, Stergios Boussios, Manel Esteller
Epigenetic alterations are a common hallmark of human cancer. Single epigenetic markers are starting to be incorporated into clinical practice; however, the translational use of these biomarkers has not been validated at the 'omics' level. The identification of the tissue of origin in patients with cancer of unknown primary (CUP) is an example of how epigenomics can be incorporated in clinical settings, addressing an unmet need in the diagnostic and clinical management of these patients. Despite the great diagnostic advances made in the past decade, the use of traditional diagnostic procedures only enables the tissue of origin to be determined in ∼30% of patients with CUP...
July 4, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28675164/antibody-drug-conjugates-in-glioblastoma-therapy-the-right-drugs-to-the-right-cells
#15
REVIEW
Hui K Gan, Martin van den Bent, Andrew B Lassman, David A Reardon, Andrew M Scott
Glioblastomas are high-grade brain tumours with a poor prognosis and, currently, few available therapeutic options. This lack of effective treatments has been linked to diverse factors, including target selection, tumour heterogeneity and poor penetrance of therapeutic agents through the blood-brain barrier and into tumours. Therapies using monoclonal antibodies, alone or linked to cytotoxic payloads, have proved beneficial for patients with different solid tumours; these approaches are currently being explored in patients with glioblastoma...
July 4, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28653677/monitoring-immune-checkpoint-blockade-response-evaluation-and-biomarker-development
#16
REVIEW
Mizuki Nishino, Nikhil H Ramaiya, Hiroto Hatabu, F Stephen Hodi
Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm shift in the treatment of advanced-stage cancers. The promising antitumour activity of monoclonal antibodies targeting the immune-checkpoint proteins CTLA-4, PD-1, and PD-L1 led to regulatory approvals of these agents for the treatment of a variety of malignancies. Patients might experience clinical benefits from treatment with these agents, despite unconventional patterns of tumour response that can be misinterpreted as disease progression, warranting a new, specific approach to evaluate responses to immunotherapy...
June 27, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28631736/haematological-cancer-staging-and-restaging-patients-with-lymphoma-a-better-approach
#17
Vijaya R Bhatt, James O Armitage
No abstract text is available yet for this article.
June 20, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28607514/evolution-of-lymphoma-staging-and-response-evaluation-current-limitations-and-future-directions
#18
REVIEW
Joel Cunningham, Sunil Iyengar, Bhupinder Sharma
The accurate detection and precise assessment of therapeutic responses is critical to the optimal management of patients with lymphoma. Over the past 50 years, dramatic advances in technology have established imaging as the cornerstone of disease evaluation. However, the appropriate application of current techniques requires acknowledgement of their strengths and weaknesses, and appreciation of the full diversity of lymphoid neoplasms. The role of anatomical and functional imaging in detection, treatment escalation/de-escalation and prognostication of patients with lymphoma can be misinterpreted...
June 13, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28561071/clinical-utility-of-gene-expression-signatures-in-early-stage-breast-cancer
#19
REVIEW
Maryann Kwa, Andreas Makris, Francisco J Esteva
Breast cancer is a heterogeneous disease, with different subtypes having a distinct biological, molecular, and clinical course. Assessments of standard clinical and pathological features have traditionally been used to determine the use of adjuvant systemic therapy in patients with early stage breast cancer; however, the ability to identify those who will benefit from adjuvant chemotherapy remains a challenge, leading to the overtreatment of some patients. Advances in molecular medicine have substantially improved the accuracy of gene-expression profiling of breast tumours, resulting in improvements in the ability to predict a patient's risk of breast cancer recurrence and likely response to endocrine therapy and/or chemotherapy...
May 31, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28534531/unravelling-the-biology-of-sclc-implications-for-therapy
#20
REVIEW
Joshua K Sabari, Benjamin H Lok, James H Laird, John T Poirier, Charles M Rudin
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor prognosis. First-line treatment has remained unchanged for decades, and a paucity of effective treatment options exists for recurrent disease. Nonetheless, advances in our understanding of SCLC biology have led to the development of novel experimental therapies. Poly [ADP-ribose] polymerase (PARP) inhibitors have shown promise in preclinical models, and are under clinical investigation in combination with cytotoxic therapies and inhibitors of cell-cycle checkpoints...
May 23, 2017: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"